Literature DB >> 27988098

Targeting MET Exon 14 Skipping Alterations: Has Lung Cancer MET Its Match?

Timothy A Yap1, Sanjay Popat2.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 27988098     DOI： 10.1016/j.jtho.2016.10.019

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  3 in total

1.  A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance.

Authors:  Li Liu; Jingjing Qu; Jianfu Heng; Chunhua Zhou; Yi Xiong; Haiyan Yang; Wenjuan Jiang; Liang Zeng; Songlin Zhu; Yongchang Zhang; Jiarong Tan; Chengping Hu; Pengbo Deng; Nong Yang
Journal:  Front Oncol       Date:  2021-10-01       Impact factor: 6.244

Review 2.  [MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer].

Authors:  Limei Yin; You Lu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-07-20

Review 3.  Response and acquired resistance to savolitinib in a patient with pulmonary sarcomatoid carcinoma harboring MET exon 14 skipping mutation: a case report.

Authors:  Sen Han; Jian Fang; Shun Lu; Linfang Wang; Jing Li; Min Cheng; Yongxin Ren; Weiguo Su
Journal:  Onco Targets Ther       Date:  2019-09-06       Impact factor: 4.147
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.